EXPERIMENTAL RADIOIMMUNOTHERAPY OF MURINE LYMPHOMA WITH I-131-LABELED ANTI-T-CELL ANTIBODIES
- 1 December 1986
- journal article
- research article
- Vol. 46 (12), 6223-6228
Abstract
We have shown previously that 131I-labeled antibodies against the Thy-1.1 differentiation antigen can cure AKR/Cum (Thy-1.2+) mice bearing AKR/J (Thy-1.1+) SL2 T-cell lymphoma. In the present study we have extended these studies to the therapy of SL2 lymphoma in AKR/J mice, where 131I-anti-labeled Thy-1.1 antibodies react with both tumor and normal T-lymphocytes. A single 25-.mu.g bolus of 131I-labeled anti-Thy-1.1 antibody was rapidly cleared from serum by binding to spleen cells (t1/2 < 3h) and only low concentrations (<2% injected dose/g) were present in tumor 24 h after infusion. Doses of 0.5-5.0 mg antibody saturated cells in the spleen but only slightly increased the proportion of antibody in tumor. In contrast, pretreatment of mice with 1.0 mg of unlabeled anti-Thy-1.1 antibody 24 h prior to 131I-labeled antibody resulted in a tumor concentration of 9.7% injected dose/g 24 h after infusion of the radiolabeled antibody. With this latter regimen, biodistribution approximated that seen in AKR/Cum mice, and infusion of 1000 .mu.Ci would result in delivery of 16 Gy to tumor. Therapy of AKR/J mice bearing established s.c. lymphoma nodules with 1500 .mu.Ci of 131I-anti-Thy-1.1 antibody given in this latter regimen resulted in complete regression of the nodule in 70% of animals and had a greater antitumor effect (27% complete regression, P < 0.001) than 750 .mu.Ci of 131I-labeled irrelevant antibody, a dose that would deliver equivalent radiation to normal organs (liver, kidney, and lung). The anti-Thy-1.1 antibody had only a slightly greater antitumor effect than an equivalent .mu.Ci dose (1500 .mu.Ci) of 131I-labeled control antibody (42% complete regression, P=0.12). Both antibodies were marrow toxic and all animals treated with 1500 .mu.Ci died of marrow aplasia. These studies suggest that radiolabeled antibodies against differentiation antigens may be useful for therapy in spite of binding to normal cell populations but curative therapy may require infusion of unirradiated bone marrow.This publication has 13 references indexed in Scilit:
- EFFECTS OF MONOCLONAL-ANTIBODY THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA1984
- ANTI-TUMOR EFFECTS OF RADIOLABELED SYNGENEIC MONOCLONAL ANTI-MELANOMA ANTIBODIES1984
- Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy.JCI Insight, 1983
- DOSIMETRY OF I-131-LABELED ANTIFERRITIN IN HEPATOMA - SPECIFIC ACTIVITIES IN THE TUMOR AND LIVER1983
- Monoclonal Antibodies in the Lymphatics: Toward the Diagnosis and Therapy of Tumor MetastasesScience, 1982
- ALTERATION OF LYMPHOID CELLS IN AKR MICE BY TREATMENT WITH MONOCLONAL ANTIBODY AGAINST THY-1 ANTIGENTransplantation, 1982
- Specific in vivo localization of monoclonal antibodies directed against the Thy 1.1 antigen.The Journal of Immunology, 1980
- Oncornaviruses produced by murine leukemia cells in cultureVirology, 1977
- RADIOLABELED ANTIBODIESAnnals of the New York Academy of Sciences, 1957
- Accumulation of Homologous Radioiodinated Albumin in Experimental TumorsExperimental Biology and Medicine, 1955